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Abstract
In their expression process, different genes can generate diverse functional products, including various protein-coding or
noncoding RNAs. Here, we investigated the protein-coding capacities and the expression levels of their isoforms for human
known genes, the conservation and disease association of long noncoding RNAs (ncRNAs) with two transcriptome
sequencing datasets from human brain tissues and 10 mixed cell lines. Comparative analysis revealed that about two-thirds
of the genes expressed between brain and cell lines are the same, but less than one-third of their isoforms are identical.
Besides those genes specially expressed in brain and cell lines, about 66% of genes expressed in common encoded different
isoforms. Moreover, most genes dominantly expressed one isoform and some genes only generated protein-coding (or
noncoding) RNAs in one sample but not in another. We found 282 human genes could encode both protein-coding and
noncoding RNAs through alternative splicing in the two samples. We also identified more than 1,000 long ncRNAs, and
most of those long ncRNAs contain conserved elements across either 46 vertebrates or 33 placental mammals or 10
primates. Further analysis showed that some long ncRNAs differentially expressed in human breast cancer or lung cancer,
several of those differentially expressed long ncRNAs were validated by RT-PCR. In addition, those validated differentially
expressed long ncRNAs were found significantly correlated with certain breast cancer or lung cancer related genes,
indicating the important biological relevance between long ncRNAs and human cancers. Our findings reveal that the
differences of gene expression profile between samples mainly result from the expressed gene isoforms, and highlight the
importance of studying genes at the isoform level for completely illustrating the intricate transcriptome.
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Introduction
Alternative splicing is a fundamental molecular process in
eukaryotes, where it not only greatly increases the diversity of
proteins that the genome can encode [1], but also contributes to
the generating of long ncRNAs [2]. Exon skipping, mutually
exclusive exons, intron retention, alternative donor and acceptor
sites are five basic models of alternative splicing, beyond that, there
are also other identified variations in splicing patterns [3,4].
Individual mammalian genes often encode multiple different
functional isoforms that may have related, distinct or even
opposing functions through alternative splicing [5,6]. A vast
variety of gene isoforms generated by alternative splicing have
specific roles in tissues or stages of development, and alterations in
the RNA processing machinery may lead to mis-splicing of
multiple transcripts and cause many diseases [7–9].
According to their protein-coding capacities, the gene isoforms
could be divided into two distinct classes: messenger RNAs
(mRNAs) which are translated into proteins, and the noncoding
RNAs (ncRNAs), which function at the RNA level. Previous
studies have indicated that most of the human genome is likely to
be transcribed, generating a complex network of diverse
transcripts that includes a large amount of ncRNAs [3,10]. Those
ncRNAs could be generated from diverse regions including
intergenic, intronic areas, some of them have been proposed
overlapping with protein-coding genes [11,12]. Due to the
majority of ncRNAs still have no clear significance in structure
and lack strong sequence conservation, it has been suggested that
they might be non-functional. In fact, a significant number of them
have been shown to have important functions [13–18]. Those
ncRNAs, which are recently identified and longer than 200 nt in
length, are arbitrarily defined as the long ncRNAs [13,14].
Previous researches have demonstrated that long ncRNAs can
negatively [19,20] or positively [21] affect the expression of
neighboring protein-coding genes. It also has been proposed that a
portion of long noncoding transcripts may be post-transcription-
ally processed to generate small RNAs [22], such as microRNAs
[23,24], Piwi-interacting RNAs [25] and etc. Evidences have
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1suggested that long ncRNAs are also associated with human
diseases and could be used as cancer biomarkers, as well as therapy
targets [26–29].
It is worth noticing that multi-exon genes could encode different
isoforms through alternative splicing and different isoforms have
different protein-coding potential. In addition, gene expression
usually exhibit temporal and spatial specificity. Therefore, the
same gene could generate different isoforms, even encoding both
protein-coding and noncoding isoforms in different conditions or
stages. RNA-Seq provides tremendous opportunities to reveal
these diversities and the peculiar specificities of the human
transcriptome [30–32]. Compared with microarrays, RNA-Seq
can theoretically capture all the transcripts in the samples.
Furthermore, RNA-Seq has low background noise, high sensitivity
and requires less sample RNA [30,31]. In principle, RNA-Seq can
achieve single-base resolution, where microarrays rely on the
density of probes. Besides, RNA-Seq can study gene expression at
the isoform level but microarrays are unable to distinguish the
isoforms and lost much valuable information related to the
characteristics of the gene isoforms, such as the protein-coding
capacity of each isoform, the number of expressed distinct
isoforms, the composition and the expression level of each isoform.
To more comprehensively illustrate the complexity of human
transcriptome, we investigated the diverse expression features of
human known genes at both gene level and isoform level based on
two RNA-Seq datasets generated from human brain tissues and 10
mixed cell lines. We first inferred the isoforms encoded in brain
and cell lines, and then assessed the protein-coding capacities of all
those expressed isoforms. Next, we compared the gene expression
profile between brain and cell lines, and revealed that there are
great differences in expression for those expressed genes between
gene level and isoform level, implying that only the isoform level
rather than gene level is able to accurately reflect the expression
profiles of human genes. We also identified hundreds of long
ncRNAs in brain or cell lines (total more than 1,000 long
ncRNAs), and found a significant number of human genes in brain
and cell lines could encode both protein-coding and noncoding
RNAs through alternative splicing. Our results show that most
long ncRNAs from brain and cell lines contain conserved elements
across 46 vertebrates, or 33 placental mammalians, or 10
primates. Through RT-PCR we further validated that several
long ncRNAs were differentially expressed in breast cancer cells
versus normal breast cells, or between lung cancer cells and
normal lung cells. In addition, those differentially expressed long
ncRNAs are significantly correlated with a number of breast
cancer or lung cancer related genes.
Results
Identifying the expressed isoforms in brain and cell lines
Our study used two transcriptome sequencing datasets from two
reference RNA samples established by the MicroArray Quality
Control (MAQC) project [33] with standard Illumina next-
generation sequencing technology: the Universal Human Refer-
ence RNA (UHRR or UHR) from 10 human cell lines of various
origins [34] and the Human Brain Reference RNA (HBRR or
HBR) from several regions of the brain of 23 adult donors (see
Materials and Methods). These two datasets consisted of ,59.46
million and ,53.24 million of sequencing reads, respectively, with
read-lengths of 35 bp.
We first mapped the brain and cell line reads onto the human
reference genome (hg19) and junction sequences using bowtie [35]
with two mismatches allowed (see Tables 1 and 2 in Document
S1). Based on the short read mapping information and the human
gene annotations of UCSC, we then inferred the expressed
isoforms in brain and cell lines [36]. Because isoforms expressed at
extremely low levels often cannot be reliably constructed, and
might be artifacts, we used 0.1 RPKM (Read Per Kilobase of
transcript per Million mapped reads) as threshold, and obtained a
total of 28,571 transcripts in brain from 16,818 UCSC annotated
genes and 32,714 transcripts in cell lines from 18,431 UCSC
annotated genes (Files S1 and S2). Lower threshold could find
more transcripts expressed, but it could also decrease the accuracy
of identified expressed isoforms due to the read mapping
uncertainty caused by the paralogous gene families, repeats and
high sequence similarity between alternative spliced isoforms of
the same gene [37]. Next, we assessed the protein-coding
capacities of all brain and cell line transcripts using CPC (Coding
Potential Calculator) [38]. In sum, 27,524 protein-coding and
1,047 noncoding RNAs were identified from the brain transcripts,
while 31,641 protein-coding and 1,073 noncoding RNAs were
found in cell lines (Figure 1). Among those noncoding RNAs, 760
(transcribed from 691 genes) in brain and 808 (transcribed from
735 genes) in cell lines are longer than 200 nt without protein-
coding potentials, they were classified as the long ncRNAs, and
380 long ncRNAs are in common between brain and cell lines.
Characteristics of brain and cell line transcripts
We then investigated the number of exons contained in each
transcripts and the number of isoforms encoded by each gene in
brain and cell lines. About 93.88% transcripts in brain and
94.73% transcripts in cell lines contained two or more exons
(Table 1). According to our selection criteria (isoform expression
level $ 0.1 RPKM as expressed), we found 11,048 (65.69%) genes
generated only one isoform in brain, and the rest expressed genes
encoded two or more isoforms. Similarly, 11,697 (63.46%) genes
in cell lines generated only one isoform, and the rest expressed
genes encoded two or more isoforms (Table 2). The average
number of isoforms each gene generated is 1.7 for brain and 1.77
for cell lines. The results suggest that the majority of human
expressed genes encoded only one isoform with a relative higher
level that can be detected, and most of those expressed transcripts
comprise two or more exons.
In brain and cell lines, 11,654 expressed genes are in common,
while 5,164 (30.71%) expressed genes only detected in brain and
6,777 (36.77%) expressed genes only detected in cell lines
according to our threshold (Figure 2A). Interestingly, in those
common expressed genes, only 3995 genes generated the equal
number and identical isoforms in both brain and cell lines, the rest
7659 genes generated different isoforms. We also found that
among those common expressed genes, 85 genes generated long
ncRNAs only in brain but not in cell lines, whereas 117 genes
generated long ncRNAs only in cell lines but not in brain; 33 genes
Table 1. Exon number of brain and cell line transcripts.
Items Brain Cell lines
Number of one exon transcripts 1,748 1,723
Number of two exon transcripts 2,281 2,429
Number of three exon transcripts 2,888 3,294
Number of four exon transcripts 3,048 3,526
Number of five exon transcripts 2,943 3,410
Number of six or more exon transcripts 15,663 18,332
doi:10.1371/journal.pone.0028318.t001
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encoded protein-coding RNAs only in cell lines. Consequently,
although most of the expressed genes in brain and cell lines are the
same, in fact, only a minority of the expressed genes generated the
same number and identical isoforms between brain and cell lines,
leaving most of them different.
To further explore the different expression profiles between
brain and cell lines, we compared the composition of all their
expressed isoforms, and surprisingly found that only 7,492
isoforms (6,990 of them are protein-coding and 502 are
noncoding) are the same between brain and cell lines, 21,079
(73.78%) isoforms (20,534 of them are protein-coding and 545 are
noncoding) are expressed only in brain, 25,222 (77.1%) isoforms
(24,651 of them are protein-coding and 571 are noncoding) are
expressed only in cell lines (Figure 2B). About two-thirds of the
expressed genes are in common between brain and cell lines, but
at the isoform level, the result is reversed and only less than one-
third of identical isoforms are expressed in both brain and cell lines
(Figure 2C). Therefore, although the majority of expressed genes
are the same between two samples, most of those common
expressed genes encoded different isoforms. Moreover, the genes
that only expressed in brain or cell lines directly contributed to the
expression differences between them. These findings further
Table 2. Isoforms of the expressed genes in brain and cell
lines.
Items Brain Cell lines
Total number of expressed genes 16,818 18,431
Total number of isoforms 28,571 32,714
Number of protein-coding transcripts 27,524 31,641
Number of noncoding transcripts 1,047 1,073
Number of long ncRNAs 760 808
Number of genes generated one isoform 11,048 11,697
Number of genes generated two isoforms 2,933 3,334
Number of genes generated three isoforms 1,352 1,548
Number of genes generated four isoforms 699 839
Number of genes generated five isoforms 352 446
Number of genes generated six or more
isoforms
434 567
In this table, only those isoforms with expression level equal or greater than 0.1
RPKM were took into account.
doi:10.1371/journal.pone.0028318.t002
Figure 1. Protein coding capacity and expression of brain and cell line protein-coding transcripts and long ncRNAs. A, B are coding
capacities of brain and cell line protein-coding transcripts and long ncRNAs, shown as the cumulative distribution of CPC scores. C, D are expression
levels of brain and cell line protein-coding transcripts and long ncRNAs, shown as the bar plot distribution of expression levels, in reads per kilobase
of exonic sequence per million aligned reads (RPKM).
doi:10.1371/journal.pone.0028318.g001
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processing of the human transcriptome.
Genes encoding both protein-coding and noncoding
RNAs
Previous evidences have indicated that some genes can encode
bifunctional RNAs, with their certain splicing isoforms acting as
regulatory noncoding RNAs, and other specific splicing isoforms
being translated into a protein, such as LXRB/LXRBSV isoform
pair [39]. Our study also revealed that 146 and 185 genes (49 of
them in common) encoded both protein-coding and noncoding
RNAs in brain and cell lines, generated 176 long ncRNAs in brain
and 217 long ncRNAs in cell lines (41 long ncRNAs are in
common), respectively. For the rest of 16,672 expressed genes in
brain (Table 2), 545 of them only produced long ncRNAs and
15,843 only produced protein-coding RNAs; for the rest of 18,246
expressed genes in cell lines, 550 of them only produced long
ncRNAs and 17,438 only produced protein-coding RNAs. These
results further demonstrate the dynamic expression patterns for
transcripts in different samples, and suggest that isoform switching
could grant the same gene with different roles according to the
temporal and spatial specificity.
To better characterize the expression features of those long
ncRNAs which transcribed from the 146 brain and 185 cell line
genes that encode bifunctional RNAs, we further compared the
exon structures of those long ncRNAs with their gene annotations
on the reference genome. We found that 13 brain long ncRNAs
contain introns, 79 brain long ncRNAs with new alternative exon
boundaries or new exons and 84 brain long ncRNAs were
produced by the exon skipping mechanism; 17 cell line long
ncRNAs contain introns, 90 cell line long ncRNAs with new
alternative exon boundaries or new exons and 110 cell lines long
ncRNAs belong to the alternative splicing events of exon skipping.
Those long ncRNAs which contain introns or with new alternative
exon boundaries or new exons might result from the intron
retention or alternative splice site usage or the incomplete
annotation of their genes on the reference genome [2,40]. Our
findings confirm that a number of human known genes can
encode both protein-coding and noncoding RNAs through
alternative splicing, showing the importance of considering the
protein-coding capacities of isoforms.
Conservation and disease association of long ncRNAs
To gain insights into the evolutionary conservation of those long
ncRNAs identified in brain and cell lines, we investigated the base-
by-base phastCons scores (see Figure 1 in Document S1) and
searched the phastCons-predicted conserved elements (see Figure 2
in Document S1) in each long ncRNA across 46 vertebrates, or
their 33 placental mammal subset of species, or their 10 primate
subset of species [41], respectively (see the ‘Conservation of long
ncRNAs’ paragraph in Document S1). We found that a portion of
long ncRNAs in human brain and cell lines are highly conserved
among vertebrates or mammals or primates and most of those
long ncRNAs contain conserved elements.
We further explored the expression profiles of long ncRNAs in
human cancers. We first aligned the probes of Human Genome
U133 Plus 2.0 Array from Affymetrix to the brain and cell line
long ncRNAs to find whether any probe can represent the
expression of our identified long ncRNAs. Using the exact and
unique match criteria, 56 probes with no corresponding gene
Figure 2. Comparison of the expression between brain and cell lines on the gene level and isoform level. A is the comparison in the
number of expressed genes between brain and cell lines. B is the comparison in the number of expressed isoforms between brain and cell lines. C is
the comparison in percentage between brain and cell line of expressed genes and isoforms.
doi:10.1371/journal.pone.0028318.g002
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for cell line long ncRNAs. Then we detected the differential
expression of those probes in two human Gene Expression
Omnibus (GEO) datasets, one is about breast cancer [42], another
is about lung cancer [43]. We found that 10 brain and 9 cell line
long ncRNAs differentially expressed in breast cancer, 17 brain
and 11 cell line long ncRNAs differentially expressed in lung
cancer, with 5 brain and 2 cell line long ncRNAs in common
between breast and lung cancers.
We then chose those five brain long ncRNAs (they are all from
the genes that only generate long ncRNAs) which were
differentially expressed in both breast cancer and lung cancer as
the candidates to validate our results with RT-PCR. All but one
long ncRNAs were obviously differentially expressed in breast
cancer cells versus normal breast cells (three of them were up-
regulation, one was down-regulation), two long ncRNAs (one was
up-regulation and the other one was down-regulation) were
apparently differentially expressed between lung cancer cells and
normal lung cells (Figure 3). These results present the feasibility of
our selected probes to represent our identified long ncRNAs to
investigate their expression profiles in human diseases. We also
found that those differentially expressed long ncRNAs have
significant correlations (r$0.4 and p,0.05) with some previously
identified breast cancer or lung cancer related genes (Tables S1
and S2), such as long ncRNA ‘‘Pred35111’’ was significantly
correlated with LEPR (r=0.66, p= 6:31|10{5), and LEPR has
reported in several studies that it involves in the pathogenesis of
breast cancer [44–47].
Discussion
In this study, we investigated the diverse expression profiles of
present human known genes based on two RNA-Seq datasets from
human brain tissues and a variety of cell lines. We found that
under our selection criteria, the majority of (more than 60%) the
expressed genes in both brain and cell lines generated only one
isoform with relative higher level that can be detected, whereas a
portion of the expressed genes could encoded more than five
isoforms. In those expressed genes of brain and cell lines, a
number of them could encode both protein-coding and noncoding
RNAs through alternative splicing, implicating the intricacy of
gene transcription and post-transcriptional RNA processing. We
also found that although most of the expressed genes in human
brain and cell lines are the same, but their expressions are
significantly different at the isoform level, and only less than 30%
of the isoforms are identical between brain and cell lines. Besides
that, some expressed genes only generated protein-coding or
noncoding transcripts in one sample but not in another. Our
results reveal that the significant difference for gene expression
profiles between brain and cell lines is not only relevant to the
sequence compositions of their isoforms, but also associated with
the protein-coding capacities of their isoforms. Furthermore, when
taking the expression level of each isoform into consideration, the
variations for gene expression will inevitably increase more
dramatically. Accordingly, only based on the isoform level, can
we accurately recognize the gene expression pattern and estimate
the gene expression profiles in various biological conditions and
different tissues, such a fine scale will definitely improve our ability
to gain new important insights into the functionalities for each
gene on the human genome.
Therefore, to comprehensively explore the differences between
different tissues, we need to consider isoforms the genes generated
in addition to identify the expressed genes. Due to the complex
alternative splicing in mammalians, the actual expression level of
multi-exon genes is not only determined by the number of distinct
isoforms they encoded, but also related to expression abundance of
Figure 3. RT-PCR validation of the expression profiles of long ncRNAs in human diseases. A is the expression profiles of long ncRNAs in
breast cancer cells (MCF-7, MDA-MB-231) and normal breast cells (MCF-10A). B is the expression profiles of long ncRNAs in lung cancer cells (A549,
H1299: non-small cell lung carcinoma) and normal lung cells (lung fibroblast). GAPDH was used as an expression control. Four long ncRNAs are all
differentially expressed in breast cancer versus normal breast cells, and two differentially expressed (‘‘Pred10150’’ and ‘‘Pred32359’’) between lung
cancer and normal lung cells.
doi:10.1371/journal.pone.0028318.g003
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present differential expression in two samples, but it does not mean
that this gene encodes the same isofoms in both samples. Because
multi-exon genes could encode multiple different isoforms through
alternative splicing and different isoforms would result in the same
expression level of the gene between the two samples. Further-
more, the multi-exon genes would even encode both protein-
coding and noncoding isoforms. Different isofroms of the same
gene could play different roles with the temporal and spatial
specificity [5,6]. Consequently, the isoform level provides us more
abilities to precisely determine the real gene expression patterns,
and would help us to refine the gene regulation network and
interaction models. However, the microarrays rely on prior
information and cannot reflect the gene expression at the isoform
level but rather at the gene level. Our study highlights the
advantages of RNA-Seq studies over microarrays for the analysis
of a comprehensive transcriptome.
We also found that the majority of brain and cell line long
ncRNAs contain the regions similar to the phastCons-predicted
conserved elements across 46 vertebrates, or their 33 placental
mammal subset, or their 10 primate subset. Consequently,
although the entire transcripts of most long ncRNAs lack strong
conservation, yet highly conserved elements are preserved in them.
In addition, some conserved element fragments of vertebrates,
placental mammals and primates in the long ncRNAs are not
similar to each other, suggesting that those conserved element
fragments provide the structural base for the corresponding long
ncRNAs to play special roles in vertebrates, placental mammals or
primates. We also observed that some long ncRNAs are
differentially expressed between breast cancer cells and normal
breast cells, or between lung cancer cells and normal lung cells,
and those differentially expressed long ncRNAs are significantly
correlated with several identified breast cancer or lung cancer
related genes. The results indicate that those differentially
expressed long ncRNAs may directly or indirectly influence the
expression of the cancer related genes. Our findings further imply
that long ncRNAs could be involved in human cancers and play
important roles in the pathogenesis of human diseases. In
conclusion, these results indicate that long ncRNAs are not
transcriptional ‘‘noise’’, but might be functional macromolecules
and they might have special relationship with cancer related genes.
Ourstudysuggeststhat tocomprehensivelyinvestigate the overall
expression profiles of human genes, it is important to consider the
following aspects: the number of distinct isoforms encoded by each
gene; the protein-codingcapability of eachisoform;the composition
of the isoforms generated by alternative splicing and the expression
levels of those isoforms and etc. Although our comparison is based
on human brain and 10 mixed cell lines, it is anticipated that the
results could also be applied to the comparison among different
tissues or cell lines. Current annotated genes on the human
reference genome are mainly about protein-coding genes and
known stable noncoding RNAs, such as tRNAs, snRNAs and
snoRNAs, only a few of those annotated genes could encode long
noncoding RNAs (some genes could encode both protein-coding
and non-coding RNAs, but these genes could be annotated only as
protein-coding genes). However, previous transcriptomics studies
have indicated that a huge number of transcripts in mammals do
not seem to encode proteins but function as noncoding RNAs
instead [2,48]. Hence a large amount of long ncRNAs transcribed
from the intergenic regions still need to be identified. Ab initio
reconstruction of the human transcriptome is crucial for the
identification of those long ncRNAs which transcribed from the
intergenic regions, With the improvements of sequencing technol-
ogies and the algorithms for ab initio reconstruction of the
transcriptome, it will enable us more comprehensively and more
thoroughly to comprehend the human transcriptome.
Materials and Methods
Data production
Two transcriptome sequencing datasets were generated from
two reference RNA samples established by the US FDA-led
MicroArray Quality Control (MAQC) project [33] with Illumina
next-generation sequencing technology. The reference RNA
sample A (UHRR, Catalog #740000) consists of total RNA
extracted from 10 human cell lines of various origins: Blympho-
cyte, brain, breast, cervix, liposarcoma, liver, macrophage, skin,
testis and Tlymphocyte [34]. Equal quantities of DNAase-treated
total RNA from each cell line were pooled to generate the UHRR.
The reference RNA sample B (HBRR, Catalog #6050) consists of
total RNA extracted from several regions of the brains from 23
adult donors.
These two samples were prepared using the standard Illumina
mRNA-Seq protocol and reagents. The sequencing data were
single end reads, with ,59.46 million and ,53.24 million of
sequencing reads in 35 bp length for cell line and brain samples,
respectively. Those two datasets from this study have been
submitted to the NCBI Gene Expression Omnibus (http://www.
ncbi.nlm.nih.gov/geo) under accession number GSE30222.
Identification of isoforms and assessing the
protein-coding capacities of isoforms
The brain and cell line reads were first aligned onto the human
reference genome hg19 (http://genome.ucsc.edu/) and junction
sequences using bowtie [35] with default parameters (allowed two
mismatches). Then we used those mapping information to infer
the isoforms transcribed from brain and cell lines base on the
human gene annotation information of UCSC by isoinfer [36].
Next, we calculated the protein-coding capacities of all brain
and cell line transcripts using CPC [38] which incorporates the
sequence features into a support vector machine to assess the
protein-coding potential of each transcript. According to the CPC
scores, we split the brain and cell line transcripts into protein-
coding and noncoding two classes. Then those transcripts which
are longer than 200nt and lack protein-coding potential were
classified as the long ncRNAs, and were used for the further
analysis.
Calculation of the conservation of long ncRNAs
We separately downloaded the base-by-base phastCons [41]
scores and the phastCons-predicted conserved elements across the
46 vertebrates, and the 33 placental mammal subset of species in
these 46 vertebrates and the 10 primate subset of species in these 46
vertebrates from UCSC (http://genome.ucsc.edu/). The phast-
Cons scores can be interpreted as probabilities that each base is in a
conserved element, given the assumptions of the model and the
maximum-likelihood parameter estimates [41]. We first calculated
the base conservation in each long ncRNAs using the criteria that
the phastCons score of base is not less than 0.9, and then we
calculated the ratio of each brain or cell line long ncRNA transcript
overlapping the phastCons-predicted conserved elements across 46
vertebrates or 33 placental mammals or 10 primates.
Detecting differentially expressed long ncRNAs and
RT-PCR validation
To investigate the disease association between long ncRNAs
and human cancers, we first aligned the probes of Human
Human Protein-Coding and Noncoding RNAs
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the probes that can represent the expression of our identified long
ncRNAs using the exact and unique match criteria. Then we
detected the differential expression of those probes in two human
Gene Expression Omnibus (GEO) datasets: GSE10810 which was
about breast cancer [42] and GSE10799 which was about lung
cancer [43]. We further checked the selected candidate differen-
tially expressed long ncRNAs using RT-PCR to validate whether
they are truly differentially expressed in breast cancer cells (MCF-
7, MDA-MB-231) versus normal breast cells (MCF-10A), and
between lung cancer cells (A549, H1299: non-small cell lung
carcinoma) and normal lung cells (lung fibroblast). Primers were
provided in Table 3 in Document S1).
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ing information mentioned in the main text.
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Table S1 Significantly correlated genes of the long
ncRNAs that differentially expressed in breast cancer.
(XLS)
Table S2 Significantly correlated genes of the long
ncRNAs that differentially expressed in lung cancer.
(XLS)
File S1 Transcript expression values, coordinates and
protein-coding capacities in brain.
(TXT)
File S2 Transcript expression values, coordinates and
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